may present with a history of easy and spontaneous bruising or gingival bleeding with tooth brushing.. Many normal individuals experience occasional gingival bleeding with tooth brushing; . however, if occurring almost daily, or more than two to three times a week, a vascular or platelet defect should be considered. Another clinical clue to the presence of a vascular disorder is the finding of dependent petechiae and purpura primarily found on the extremities and usually absent from the torso. This is a characteristic of vascular bleeding, whereas platelet defects are typically associated with symmetrical petechiae and purpura found on the extremities and torso. If microvascular disorders are manifested by occlusion, -likewise, --the findings are -usually dependent our distal. __ Common clinical findings of vascular disorders are summarized in Table l ~ l-~). When suspecting a vascular disorder, one must first rule out coagulation protein defects (prothrombin time and activated partial thromboplastin time) and thrombocytopenia. If these are normal, in the appropriate setting, the differential diagnosis is, therefore, a vascular defect versus a platelet function defect. If the distinction cannot be made clinically, the most reliable method of diagnosing a vascular defect is to document normal platelet function. In the past, prolongation of the standardized template bleeding time (TBT) has been used to document the presence of vascular nr pl4tt~t~t dysfunction; however, this test is very unreliable for this particular use. Thus, when suspecting vascular dysfunction, the appropriate ways to rule out platelets dysfunction are platelet aggregation or Lumiaggregation studies or use of the newer PFA-100 or Thrombostat 4000 platelet function analyzers (4) (5) (6) . Once platelet dysfunction is ruled out, vascular dysfunction is lih:ely.
CLINICAL VASCULAR DISORDERS
Vascular disorders are best categorized as hereditary, acquired, and drug induced. These are summarized in 'T'able 2. The hereditary vascular disorders -generally are the hereditary collagen vascular diseases and most are rare clinical oddities. The one exception to rarity is Osler-Weber-Rendu disease (hereditary hemorrhagic telangiectasia [HHTI) , which is common. Alternatively, the acquired vascular disorders are very common and all clinicians should be familiar with them. The importance of becoming familiar with acquired vascular disorders is several-fold: when a patient presents with dependent petechiae and purpura, and easy or spontaneous bruising or ' the other clinical manifestations of vascular dysfunction previously discussed, the patient should be evaluated for . vascular disorders. Atso, if an individual has one of the acquired disorders known to be associated with vascular defects and undergoes surgery sustain trauma, iti should be assumed the patient has a systemic vascular defect that might lead to clinically significant thrombo-1 i hemorrhagic problems. ! Vascular disorders may present in bizarre and varied' ways. The reasons for this are the many complex deter-' minants seen in individual patients, which may alter clinical findings. These determinants, which account for i varied clinical presentations, are summarized in Table 3 .
There are many potential host responses to a vascular I disorder or defect. For example, there may be simply an ' antigenic response, or may only be activation of the co-I agulation system, activation c~f f'tbrinolysis, kinin activation, activation of only complement, or any combinations ¡ . TABLE 1. ~&dquo;firzichuf ~n~in~~~ in ~3usc°r~fcir c~i.s~~cises Of these activation pathways. Also, there are differing severities of vascular insults, injuries, or diseases. A mild vascular insult (disorder) will usually lead to only serum effusion, which clinically is interpreted as bullae and erythema. However, if the insult (disease) is more pro-.nounced, both serum and blood may effuse from the ,vasculature, giving rise to bullae, erythema, and wheals in association with petechiae and purpura. If the insult is severe, there will not only be effusion of blood, but alsõ :ncloth~li~l cell death and petechiae and purpura and ,.,ross hemorrhage, often large ecchymoses, and small or !arge vessel thrombosis. In addition, the other dermal manifestations previously discussed may be present. The ' findings may or may not be consistent on any given ' examination. When the myriad host responses to a vascular disorder are integrated with the severity of the vascular disorder or insult, it becomes obvious how many seemingly similar vascular disorders may present with varied clinical findings, thus taxing the clinical acumeñ ,;f the clinicians.
' HEREDITARY VASCULAR DISORDERS -The hereditary vascular disorders are summarized in° Table 4 . These are Ehlers-Danlos syndrome (EDS), t ~' (PE) , homocystinuria, giant cavernous hemangiomata, and the Kasabach-Merritt syndrome (the combination of giant cavernous hemangiomata and disseminated intravascular coagulation) and HHT. Each of these disorders will be discussed separately.
hl~rr~---I~anlas syndrome
Ehler-Danlos syndrome is a rare connective tissue disorder usually inherited by autosomal dominance ~'~). Interestingly, one of the earliest descriptions of this syndrome may have concerned the violin virtuoso Paganini; this disorder was thought to contribute to his remarkable dexterity and talent. Ehler-Danlos syndrome is variable in inheritance, variable in pathophysiology, and highly variable in phenotypic dinical expression. There are at least nine types of EDS, and are referred to as EDS types I through IX. In general, EDS is characterized by extreme vascular fragility, skin fragility, hypermobile joints, and 'mc~lluscc~id pseudotumors of the knees and elbows. Joint pain, particularly of the shoulders, hands, and knees, is a prominent feature (8) . Bleeding may be highly variable; however, easy and spontaneous braising is a hallmark. Patients commonly have gingival bleeding with tooth brushing and have severe bleeding after dental extraction. Also, petechiae, purpura, gastrointestinal bleeding, and hemoptysis are often present. In some instances, the bleeding may be severe enough to suggest hemophilia. Some may have associated platelet dysfunction (4, 9) . Other characteristics commonly noted (12, 13) . Indeed, individuals with either childhood aneurysms or any patient with multiple aneurysms should be suspected of harboring EDS; these are most common in type IV. Many individuals with EDS have intracerebral aneurysms. It is thought that about 5% of intracerebral aneurysms are congenital, and EDS type IV is prominent among these (14) . Despite the catastrophic vascular consequences of EDS, one investigation failed to demonstrate abnormalities or alterations in vascular wall mechanics in patients with EDS (15) .
Ehler-Danlos syndrome type I is a severe form of the disease (16) and appears to be the result of mutations in the COL5A2 gene on chromosome 9 (17), leading to abnormalities of type V collagen (18, 19) ; this same defect is also thought to account for EDS type II (20). The pathophysiology of EDS types III, V, and VIII are obscure. Ehler-Danlos syndrome type IV is also a severe form of the disease and although patients with this variant harbor the problems previously depicted, they are particularly prone to aneurysms, vascular rupture, and hepatic or colon rupture (21-24). Ehler-Danlos syndrome type IV is due to a mutation in the COL3A 1 gene, which codes for type III procollagen, leading to abnormal type III collagen (25-28), Ehler-Danlos syndrome type VI, unlike the other forms, is inherited as an autosomal recessive trait and is due to abnormally low lysyl hydrolase activity (29) secondary to a defect of the lysyl hydrolase gene (30-32). Ehler-Danlos syndrome type VII is due to a defect in type I collagen; this is brought about by a mutation in the COL I A I or Ct3L I A~ gene.
Those with mutations of the COL1A1 gene have a more severe form of the disease than those with the COLIA2 mutation (33). As previously noted, the pathophysiology of EDS type VIII remains obscure. Ehler-Danlos syndrome type XI is due to unclear abnormalities in copper metabolism; this to severe reductions in lysyl oxidase, which, in turn, leads to abnormalities of collagen and elastin cross-linking (34). The common laboratory findings are a prolonged TBT and, sometimes, abnormal platelet aggregation if the patient has an associated platelet function defect. A prolonged TBT is classically present. Therapy for bleeding depends upon the site and severity ; however, I -desami no-8-D-argi nine vasopressin (DDAVP) has been successful in controlling not only mucosal surface bleeds but also bleeding associated with surgery or dental extraction (35). If platelet dysfunction is documented, platelet concentrates should also be can-; sidered for significant bleeds. The treatment of large an-; eurysms, colonic rupture, or vascular rupture is obvi-i ously surgical. Cerebrovascular aneurysms are neitheri neurosurgical nor treated by the modalities discussed inl the section on HHT. Characteristics of EDS are summa-r ized in Table 5 ¡ disease is advised and has been shown to be associated with reduced mortality at 8 years (43). In a study assessing the outcome of pregnancy in Marfan syndrome, it was noted that aortic dissection is clearly a complication of pregnancy, occurring in 17% of patients without prei conception aortic problems. It was also. concluded that I preconception aortic root may often, but not ! always, be a reasonable predictor of this complication (44) . Another catastrophic event in Marfan syndrome is ! that of retinal detachment; in a recent study, 89% of '1 uncomplicated detachments were successful repaired and a 56% success rate was noted with complicated de-I tachments (45) As with other hereditary collagen vascular disorders, cerebral aneurysms are a problem; a recent ! assessment of autopsy cases revealed 28% of patients to have multiple cerebral aneurysms (46). An additional ; interesting complication of Marfan syndrome is sleep pn~,a, presumably due to maxilla and high-arched palate 1 owing to faulty, relaxed connective tissue, which leads to ! this increased upper airway collapsibility (47, 48) . There are no characteristic hemostasis laboratory characterisi tics; however, a prolonged TBT may be present (4) The characteristics are summarized in Table 6 .
Osteogenesis imperfecta (brittle bones and blue
-!sc!erae syndrome) ..
Osteogenesis imper6ecta is also one of the more com-; mon hereditary collagen vascular disorders and is inher-; ~~e~ as an autosomal dominant trait. The genetic abnor-! matity appears to reside in mutations of the Coli Al our CoMA2 gene, leading to abnormalities of type I collagen (49) (50) (51) (52) (53) (54) . This disorder is characterized by a patchy lack of bone matrix. However, the existing matrix undergoes normal calcification. Osteogenesis imperfecta is clinically manifest as deformed and brittle bones that fracture I easily. The primary clinical problems are orthopedic, with many patients requiring intramedullary shaft and nail repairs of the femur and tibia (55 (4, 61) . Also, many cases have been described with abnormal platelet function, as defined by aggregation studies. The basic pathophysiology of osteogenesis imperfecta is the inability of reticulin to mature into collagen; the collagen present contains an abnormal amino acid composition. Characteristics of this syndrome are summarized in Table 7 .
Pseudoxanthoma elasticum
Pseudoxanthoma elasticum, unlike the other hereditary vascular diseases, often does not become manifest until the second or third decade of life (4, 62) . This very rare disorder is usually inherited as an autosomal recessive trait, but autosomal dominant forms have also been described. Regardless of mode of inheritance, the genetic defect has been mapped to chromosome ' 1 ~~ l ~.1 ' (63). Pseudoxanthoma elasticum is commonly characterized by significant hemorrhage because abnormal elastic fibers involve the entire arterial system. Vascular proteoglycans are also abnormal (64) and elevated markers of endothelial damage, including endothelin-1 and von Willebrand factor, have been described (65) . Hemorrhage happens in any organ, but most commonly involves the skin, eyes, kidneys, central nervous system, and gastrointestinal tract (66) (67) (68) . Also, these patients have a marked tendency for easy and spontaneous bruising and commonly have petechiae and purpura. Also, these individuals have a marked predisposition to thrombosis, especially cerebral vascular thrombosis, acute myocardial infarction, and peripheral vascular occlusion with resultant gangrene and loss of extremities (69, 70) . Other clinical characteristics include relaxed, inelastic, and redundant skin in facial, neck, axillary, orbital, and inguinal areas. Hyperkeratotic plaques develop in these areas and subcutaneous calcinosis is also common. Angioid streaks are characteristic ocular findings (71, 72) . Death is frequently caused by gastrointestinl hemorrhage (4) . Excessive uterine bleeding and intra-articular bleeding with the formation of characteristic hemarthroses are c~m-mon. The basic vascular pathology of this disorder is unclear, but thought to be caused by metabolic (enzyme) defects in elastic fibers (4) . This syndrome is summarized in Table 8 . 1 Homocystinuria ~nd h~p~rh~ma~ystin~miH omocystinemia may be a hereditary or acquired disorder. The classic hereditary form results in severe clinical symptomatology during early childhood. The most common hereditary form is due to a deficiency of cystathionine beta synthetase; the homozygous form is seen ' (73, 74) . The gene responsible is located on chromosome 21 q2~. ( 74) . Patients have decreased levels of cystathionine beta synthetase, which leads to characteristic homocystinemia, methioninemia, and homocystinuria. A second inherited form is due to deficiencies of enzymes in the remethylation pathway. The enzyme methylenetetrahydrofolate reductase (MTHFR) is responsible for the conversion of 5,10-methelene tetrahydrofolate to 5-methyl-tetrahydrofolate. Individual homozygous for this enzyme deficiency are much rarer than those with ' ' cystathionine beta synthetase deficiency; the clinical pictures are similar. Heterozygous deficiency of MTHFR renders homocysteine levels, which are adequate to protect against neurologic, but not vascular deficiencies. A thermolabile mutant of MTHFR occurs in neurologically normal individual and this defect may be quite common (75, 76) . Another very rare inherited form of homocystinemia may be due to deficiencies/mutations of the cobalamin coenzyme synthesis enzymes (77, 78 (80) . Also, widespread atheromatous changes happen in patients at an early agẽ~ 1 ). Homocystine-induced endothelial cell damage with resultant patchy endothelial cell sloughing and, later, ' platelet-induced intimal proliferation of smooth muscle media cells occur, leading to widespread atheroma formation. The acquired forms of hyperhomocystinemia come about via deficiencies of cobalamin (B,2), folate, or pyridoxine (B~~ deficiencies. These acquired forms are also thought to account for many instances of arterial and venous thrombotic and atherosclerotic/occlusive events. Interestingly, as women become postmenopausal and the risks of atherosclerosis increase, so do plasma homocysteine levels; this is often reversed with estrogen replacement therapy. Elevated levels of homocysteine i are also associated with increasing age, male sex, cigar i rette smoking, elevated cholesterol, hypertension, and I sedentary lifestyle. Clearly, epidemiologic and dinical I prospective studies have shown hyperhomocystinemia to . 1 be associated with a variety of thrombotic events, with I about 50% being arterial and 50% being venous, or com-' . 1 binations thereof (77) The arterial events include periph-I eral arterial thrombosis, (78,79) coronary artery thrombosis (78, 80) , and cerebrovascular thrombosis (78, 81) . i
The mechanisms of thrombosis and atherosclerosis in-I duced by hyperhomocysteine appear to be multitaceted, ! Homocysteine is directly toxic to endothelial cells, and I I .
has been shown to increase endothelial free radical production and subsequent lipid peroxidation. The toxic ef-; fects on the endothelium appear to interfere with ad-¡ equate endothelial production of EDRF. Homocysteine has been shown to have a growth-promoting effect on smooth muscle cells and, concomitantly, an inhibitory effect on endothelial cell growth; this combination may lead to atherosclerotic occlusion. Platelet dysfunction may also arise from elevated homocysteine levels; these changes consist of increased platelet adhesion (82) and increased thromboxane A-2 release (83). Also, elevated levels of homocysteine have been reported to antivate factors XII and V and inhibit endothelial throm-' bomodulin (84-87). Thus, there may be multiple mechanisms that lead to thrombus and atheroma formation in hyperhomocystinemia. Although not all authors agree, the diagnosis may generally be made by a fasting total (reduced and oxidized forms) homocysteine ie~el (7~,'~7). S~me; hc»ever, feel that methi6nine loading should he' done because some heterozygotes for cystathionine beta synthetase deficiency have demonstrated normal fasting homocysteine levels (88,89); in this instance, a methionine load of 100 mg/kg was given just after an overnight fast. Homocysteine levels are drawn immediately before 2, 4, 6, 8, 12, and 24 hours. It is likely that the majority of patients with clinically significant hyperhomocystinemia will, however, be detected by simple fasting homocysteine levels.
Homocysteine levels may be decreased by the use of pyridoxine (50 mg/day, p.o.), folate (1 mg/day, p;o.), and, at times, vitamin B12' Use of these vitamin supplements is benign and, although not always effective, many complications and thrombotic episodes can be reduced with their use. Acute thrombi should be treated as usual, depending upon the particular clinical situation and event, but some thrombotic manifestations have been successfully controlled with combination platelet suppressive therapy consisting of dipyridamoie and aspirin i (4). Ticlopidine and clopidogrel may also prove effective. Several excellent reviews on this complex topic are ! available (73, 77, 90, 91 Hereditary hemorrhagic telangiectasia is a common disorder and is the most common hereditary vascular disorder leading to a hemorrhagic diathesis (103-105). The disorder is inherited by autosomal dominance, with 70% of affected individuals having a positive family history (4). The incidence is between 1 in 2,000 and 1 in 3,500, but because the disease is so underdiagnosed, these are probably gross underestimates (106,107). The homozygous state is thought to be lethal. The gene responsible for HHT is somehow linked to blood group 0 (4) . There are at least two forms of the disease: HHT I and HHT II. HHT I is more common. HHT I has been mapped to abnormalities in chromosome 9q33-34, which codes for the ~ndc~~~Iin gen~ ~ (108,109). Endogulin is an endothelial glycoprotein membrane receptor for transforming growth factor beta (TGF-P), and the absence of endogulin receptors is thought to lead to abnormal (although usually local) vascular defects, including proliferation, adhesion, and extracellular matrix composition and organization (l 10), leading to the telangiectatic lesions. HHT II involves a defect of chromosome 12q ~ 3 involving the activin receptoruke kinase I gene (ALK-1~, ~ serine-threonine receptor found mainly on vascular endothelial cells (I 11) and, like endogulin, binds TGF-P.
The defect(s) appear to be due to defects in endothelial cell junctions ( I 1~~, incomplete formation of vascular elastic fibers, and vascular smooth muscle cell formation (113) 14) .
The clinical manifestations of the two forms appear to be si~ni~ar, except for the incidence of pulmonary arteriovenous fistulae, which appears, in one preliminary report, to be about 30% in I and only 3% in HHT H (115) .
In both forms of HHT, the vascular lesions may involve almost all sites, including any mucosal surface, the gastrointestinal and genitourinary tract, the pulmonary circulation, the circulation of the central nervous system, and almost any other area. Because of this, the clinical manifestations may be highly varied, complex, and taxing to the clinician. The most serious sequelae of HHT are the pulmonary and central nervous system manifestations. Because significant pulmonary arteriovenous fistulae or malformations ~~4~~s~ may occur, patients may also demonstrate significant arterial oxygen desaturation, leading to clubbing, abnormal arterial blood gases, polycythemia, cyanosis, and occasionally, frank heart failure. On rare occasion, hepatic cirrhosis and failure may occur. The hallmark characteristic of this disease is epistaxis, which may be profuse and usually begins in early childhood. Epistaxis, if severe enough, can be controlled with electrocauterization (116) or Nd:Yag laser ablation (117, 118) . The classic telangiectatic lesions of HHT may not appear until later in life, commonly the second or third decade. The classic diagnostic triad of HHT is as follows: l ) a hereditary basis (70%); 2) telangiectasia ; and 3) bleeding from telangiectatic lesions 4~: 6°~hra~ic hlc~c~d l~r~s, ~c~m~nonly fc~rn Eh~ ~ustcc~int~s-' (4) . Chronic blood loss, commonly from the gastrointestinal or genitourinary tract, is often severe enough for patients to present with iron deficiency anemia of unknown etiology.
The telangiectatic lesions of HHT may be of three types: pinpoint, nodular, and spiderlike ~~,1 I 3}. Although HHT is found in most, if not all, ethnic groups, the lesions may be very difficult to detect in hyperpigmented races such as blacks and Asians. Unlike telangiectasia associated with chronic liver disease, those of HHT are nonpulsatile (4). Telangiectasia and bleeding, especially gastrointestinal, usually increase with advancing age, although epistaxis often decreases with age (4). The bleeding of HHT may be a ~c~~~rt, but common of gasuointestinal or ,g~~itc~urin hemorrhage, hemoptysis, or heavy menstrual flow. Successful control of excessive menstrual flow has been noted with use of leuprolide followed by electrocauterization (120). About 20 to 30% of patients develop arteriovenous fistulae of the pulmonary vasculature (121) . Solitary pulmonary fistulae appear more common than multiple site pulmonary fistulae l ~~) and are much more common in HHT type 1. Significant clinical problems resulting from pulmonary fistulae (hemoptysis, shunting, or central nervous system manifestations) may be treated by photodynamic therapy (123) , coil embolization 1 124), or surgical removal (125) . Hepatic AVMs may develop in about 55% of patients, ' and there is an inordinately high incidence of Laennec's type cirrhosis in these patients (4, 126, 127) . Hamartomata of the liver and spleen may also be associated with HHT { l 2~}. The most serious problem in HHT involves central nervous system manifestations, which may occur in up to lsbk of patients with HHT. Patients with pulmonary AVM have a high incidence of central nervous system infections, most commonly abscess formation but also meningitis (129) . These complications arise in at least 5% of patients with pulmonary AVMs. Other central nervous system manifestations include recurrent transient cerebral ischemic attacks (emboli or small thrombi), overt cerebrovascular thrombosis, intracranial hemorrhage (2 to 3% of all patients with HHT) (rupture of telangiectatic lesions or central nervous system t~V~s), and spasms of cerebral vasculature (130, 131) .
Successful treatment for significant cerebral telangiectasia or AVM has included endovascular embolizatioñ I 32): surgery, or gamma knife radioneurosurgery (133) .
Because of the serious pulmonary and central nervous system sequelae of HHT, all patients should be considered candidates for screening for both pulmonary and central nervous system arteriovenous malformations.
There are few characteristic laboratory findings in HHT. The TBT may be normal or abnormal, depending on the integrity of the vasculature, in the particular area where the test is done (4) . The diagnosis is suggested by a history of recurrent bilateral epistaxis, usually first noted in early years; occult gastrointestinal bleeding; and the noting of nonpulsatile pinpoint, nodular, or spiderlike telangiectasia, most commonly found in the skin, sublingual and perioral areas, the buccal mucosa, or under the nails (4).
Hereditary hemorrhagic telangiectasia is often associated with other defects in hemostasis. Abnormal platelet function is present in many patients with HHT (4, 134, 135) . Also, a poorly defined defect in the fibrinolytic system may occur (136, 3 ) . Of major importance, and often unappreciated, is an associated DIC syndrome. DIC is often present in a low-grade form but periodically may become fulminant. If looked for, DIC is found in about 50% of patients with HHT; one study, however, did not find DIC in a population of patients with HHT (138, 139) . In some patients, bleeding may be severe enough that spontaneous intra-articular bleeds, and re-; sultant hemarthroses, develop. HHT may be somewhat j similar to the syndrome of giant cavernous hemangio-I mata and DIC; hence, a '~mini'~ :~asab~ch-Merritt syn-; drome manifests in some patients, though it is often note recognized (4) . When DIC happens, treatment should be ; I targeted at stopping or blunting the process before a ful-'m inant stage is attained (4, 140) . Characteristics of HHT. are depicted in Table 9 . ' (142) . Specific therapy for significant bleeding associated with congenital vascular defects other than HHT is generally not satisfactory and depends primarily upon supportive measures and control of the underlying disease process.
ACQUIRED VASCULAR DEFECTS
The common acquired vascular defects are summarized in Table 10 . It is important to be familiar with these defects, as they are quite common. Patients presenting i with easy and spontaneous bruising, petechiae, and purpura, especially dependent, and other suggestive historical and physical findings should be suspected of having, and be evaluated for, the disorders associated with acquired vascular defects. Alternatively, if an individual has one of these disorders and is going to have surgery or experience trauma, it can be assumed a systemic vascular defect is probably and that significant hemorrhagic or thrombotic problems may follow. The common acquired diseases associated with systemic vascular problems leading to systemic hemorrhagic problems inj elude the acquired collagen vascular disorders, circulating immune complex disorders, multiple myeloma, Walj densuom macroglobulinemia, cryoglobulinemia, amyloidosis, Cushing syndrome, diabetes mellitus, the allergic (Henoch-Schonlein) purpuras, many infectious agents, and drug-induced vascular defects (4) .
In collagen vascular disorders, the vascular hemorrbagic defect is thought to be because of poor vascular support from intrinsic collagen abnormalities. In Cushing syndrome it is thought that the vascular disorder, and typical hemorrhage occurring, is caused by abnormal mucopolysaccharides in perivascular supporting tissue. AU the paraproteins, including immunoglobulin (Ig) A, IgM, and IgG, have an affinity for attachment to the vascular endothelium and lead to a vascular hemorrhagic problem. This is most commonly noted with IgM and IgG3 paraproteins. Also, paraproteins may occlude the vasa-vasorum of affected vasculature, again giving rise to hemorrhage (4) . Aspirin is commonly regarded as a platelet function inhibitor. However, aspirin is also a very effective inhibitor of acetylcholine esterase; this leads to a vascular bleeding problem (143) . If a patient is ingesting aspirin and trauma (or microtrauma in the form of a TBT) ensues, prolonged vascular bleeding may happen. The usual vascular response to trauma is constriction. With vascular trauma, acetylcholine esterase degrades acetylcholine, which keeps the vessel dilated; trauma-induced release of catecholamines will constrict the vessel. If the patient is taking aspirin and the vasculature is severed, acetylcholine esterase is inhibited, acetylcholine cannot be degraded, and inadequate vascular constriction results (4) . Prolongation of the TBT after aspirin ingestion may be resulting from the vascular, instead of platelet, inhibitory effect (4).
Malignant paraprotein disorders and amyloidosis
The many thrombotic and hemorrhagic tendencies in patients with malignant paraprotein disorders and amyloidosis, be they primary or secondary, are well recognized. Also, these disorders can present with a wide clinical spectrum of hemorrhagic and thrombotic problems, depending on host response, size, and site of the vasculature involved, and response of the particular endorgan. There have been many proposed mechanisms for the vascular complications of malignant paraprotein disorders and only the salient features of most of these Disseminated intravascular coagulation is also seen in patients with malignant paraprotein disorders. Whether this is because of endothelial damage by paraprotein or by other unexplained mechanisms is unclear. Also, the fibrino(geno)lysis occurring in patients with malignant paraprotein disorders is initiated through unclear mechanisms. This might represent ~ibrinc~Iysis secondary to DIC, fibrinolysis secondary to endothelial damage, or may result from deranged endothelial plasminogen activator activity (147) . : Amyloidosis further complicates the vascular changes of malignant paraprotein disorders, and is associated with increased hemorrhage or thrombosis via disruptions of the vasculature. Classically, primary amyloidosis is of unknown etiology or associated with malignant paraprotein disorders. Primary amyloidosis characteristically involves the skin, tongue, heart, and gastrointestinal tract, while secondary amyloidosis is seen with chronic inflammatory/infectious diseases and typically involves the liver, spleen, kidney, and adrenal glands (148). However, many &dquo;cross-overs&dquo; and mixtures of the two are ~..~. commonly seen, and sometimes one cannot precisely define amyloidosis as being primary or secondary (148). Although there are many proposed mechanisms for vas-culitis in primary and secondary amyloidosis, precise mechanisms are unclear. Vascular hemorrhage is a hallmark of amyloidosis, and is manifested 'as petechiae and purpura, ecchymoses, easy and spontaneous bruising, including spontaneous hemorrhage into nodes, re-j current hematuria, and spontaneous hemorrhage into vital organs (4) . Several proposed pathophysiologic events leading to generalized vasculitis have included antigenantibody complex-induced endothelial damage or deposits of amyloid on the endothelium and in the perivascular areas (149) . Endothelial and perivascular amyloid deposits are more commonly appreciated in the secondary forms, especially in arterioles. This leads to both a hemorrhagic and thrombotic tendency. In secondary amy- ' laidc~~is, amyloid deposits are noted along the endothe--' lium; intimal deposits start in the intima and progress to the media, with amyloid being deposited in parallel with reticulum fibers instead of around the collagen fibers, just as it is in primary amyloidosis. In primary amyloidosis, the deposits are usually seen along the collagen, with progression from the adventia to the media of arterioles and veins. The same process appears to happen in I veins, possibly accounting for the thrombotic tendencies .. seen in these individuals.
:
In some patients with systemic amyloidosis, acquired factor X deficiency occurs (150) (151) (152) (153) (154) (155) (156) . I n two patients similarly affected, an acquired combined deficiency of factors IX and X was noted (156) . Furie et al. (157) explored the mechanisms of factor X deficiency in yloidosis using 13lI-label factor X. A triphasic plasma clearance pattern was noted; 85% of the labeled factor X cleared in less than 30 seconds, about 10% in less than 9tJ' seconds, and the remaining 5% was absent in l t~..~ hours. Subsequent surface scanning of the patients 24 hours after the labeled infusion showed high concentrations in the liver and spleen. This observation, coupled with the rapid clearance of the label on initial transit in the circulation, led these investigators to conclude that the factor X is deposited at prior tissue sites of amyloid. These ' cases should respond to therapeutic infusions with factor II, VII, IX, and X concentrates; however, only a transient correction by concentrates in factor X-deficient of amyloidosis is noted (4) . The variability of hemorrhagic and thrombotic manifestations in patients with ' tein disorders and arny~didas~s ulill d~pend upc~n th~ particular end-organ involved and the of vascular permeability and/or occlusion. ' In summary, patients with malignant paraprotein disorders and amyloidosis may develop a diffuse vascular disease that may manifest as hemorrhage, thrombosis, or < bath. A high variability of end-organ damage may be ~' seen. It is important to appreciate that these patients may < experience significant vascular bleeding, and bleeding < from obvious other causes, when subjected to surgery or trauma. Also, when evaluating patients with vascular dis-orders, malignant paraprotein defects or amyloidosis should be considered in the differential diagnosis. When a selective acquired factor X deficiency in an adult is found, underlying systemic amyloidosis should bẽ trc~ngly suspected.
Autoimmune disorders and vascular defects
Immunologic diseases associated with circulating immune complexes, especially those associated with circulating cryoglobulins, are of paramount importance as disorders associated with a diffuse v~;sculitis and resultant thrombosis or hemorrhage. least three potential mechanisms by which circulating immune complexes, ~ircul~ting crycsglc~bnlrn~, or circulating antibodies may lead to vasculitis have been described: 1) the production of an antibody that is directed specifically against the endothelium (I~8) (this is the least common operativẽ mechanism); 2) the production of a nonspecific antibody or immune complex that ndnsp~cifically attacks and damages endothelium and other cellular systems (159); and 3) the generation of an antibody or immune complex ! that attaches to and damages p~ri~~s~ul~.r tissues (including basement membrane), and secondarily c~uses endu-; th~lial damage and increased vascular permeability I (!60). The vascular responses and clinical manifestations ! are variable and depend upon severity, duration, and degree of repetition of endothelial or peri~ndc~theli~l insult and damage (161) . If the attack is mild, then increased vascular permeability, fibrin deposition, and a fibrinolytic response will occur, with minimal hemorrhage and thrombosis (4). I~, hc~~~v~r; the insult is persistent, there is excessive endothelial damage, depletion of tibrinc~lyti~ ' enzymes and endothelial fibrinolytic activators, increased fibrin and platelet deposition, more pronounced thrombosis or hemorrhage, and more enhanced and perpetuated ~nd~?th~Iial damage. 'In more severe insults to ! the ~ndc~th~lium or surrounding tissue by ~nti y,'imjune tfc~~np~~x, c~r cryogl~hulins, endothelial death, sloughing, and more severe thrombosis, hemorrhage, and ! end-organ failure may foltsaw: Antibody directed specifically against the endothelium is a rare mechanism of I autoimmune-induced vasculitis and is limited to the allergic purpuras (e.g., He~aeh~;~~hc~nlein) a.nd pca~ya.rteri-I tisnodosum ( 158) . However, future immunologio investigations may define other disorders in this class. The other two of immune complex-induced vasi culitis are more common and are seen in a variety of autoimmune disorders. In many of these diseases, circu-lating>immune complexes ~Ig~i and IgM) attach to the ! endothelium, fix complement, and induce migration of ,Ieukocytes, which disintegrate and destroy the vessel ( 162) . For example, all are familiar with the results :of antistreptococcal antibody attaching to the glomeruilar endothelium or basement membrane, giving rise to later renal vascular damage (163) . An extension of this is Goodpasture syndrome, in which antibody or immune complexes are directed against both renal and pulmonary basement membrane, with associated resultant endothelial damage and thrombohemorrhagic manifestations.
Many infectious agents are known to be associated on rare occasions with vasculitis and the attendant clinical manifestations mentioned earlier. These include ' ' many bacterial, viral, and Mycoplasma infections. The mechanisms, where known, include the induction of nonspecific antiendothelial antibody by the invading organism, the inducement of specific antiendothelial antibody by the invading micro-organism, and the development of circulating immune complexes (164) (165) (166) (167) . The above mechanisms were described earlier. Table 11 I lists the most common infectious agents associated with a vasculitis.
In most circulating immune complex diseases, the injury is nonspecific and not only the endothelium but many other cellular systems are damaged. Diseases with circulating antibody, immune complex, or cryoglobulininduced vasculitis are many and include collagen vascular disorders, drug reactions, serum sickness, and a large group of seemingly unrelated disorders. Table 12 summarizes pathophysiologic mechanisms. Table 13 depicts the most common disorders that fit into this category of acquired diseases associated with circulating immune complex, resultant endothelial damage, vasculitis, and clinical thrombohemorrhagic manifestations (4).
Ialignant hypertension, eclampsia, Cushing diseases, diabetes mellitus, and vascular defects
Patients with malignant hypertension, advancing age, or diabetes mellitus deposit lipohyalin material (fibrin) in the subendothelium of arteries and arterioles (4) . In ma- lignant hypertension, fibrinoid necrosis is another characteristic feature. Because constant, unrelenting damage happens, the vessels eventually develop increased vascular permeability, with plasma seepage and fibrin deposition. This leads to thrombosis and thromboembolism, a common clinical problem in these disorders (168) . The resultant downstream capillary stasis leads to the development of chronic purpura and local hyperpigmentation of the skin, resulting from chronic hemosiderin deposits. The reader is referred to authoritative reviews for more complete pathophysiologic events in these disorders (169-17 1) . The findings in eclampsia are similar to those described earlier, with the development of hypertension and localized intravascular coagulation, (fibrin deposition) in the placental and renal microcirculation ( 72, 7 73) . Some women develop classic findings of either chronic or acute DIC with any or all the Clinical manifestations of DIC (97,174).
The vascular changes of Cushing disease are poorly defined, but include loss of subcutaneous elastic tissues leading to inadequate endothelial cell support, increased vascular permeability and fragility, and loss of elastic tissue in the vascular wall; (4) . Also, advanced atherosclerotic changes occur in larger vessels (175) . Easy and spontaneous bruising is seen in most patients with Cushing syndrome, as is a marked increase of thrombosis and thromboembolic disease (4). Many patients with Cushing (4) .
Behcet syndrome
Behcet syndrome is most commonly, but certainty not exclusively, seen in people from the Mediterranean areas and Japan (176) , and is typically characterized by a typical triad of aphthous stomatitis, genital ulcerations, and iritis (177) (178) (179) . Also, many patients develop recurrent deep venous thrombosis of unexplained pathophysiologic origin, usually involving large veins, the saphenous veins, sagittal and dural sinus thrombosis, portal and hepatic vein thrombosis, and superior and inferior vena cava thrombosis (180) (181) (182) . Many patients with superior vena cava thrombosis present with or develop superior vena cava (SVC) syndrome (183) (184) (185) . Of patients developing thrombosis, about 609h are venous, 30% are arterial events, and about 109k are both arterial and venous (186) . Aneurysms have also been reported l ~'1~. : Many patients develop a widespread, poorly defined ar-I teritis (188) . Patients may show fibrinoid necrosis of the arterial tree (189) . Case reports have documented im-' : paired fibrinolysis, and some patients have responded to i thrombolytic therapy (190) . Except the finding of impaired endothelial fibrinolytic activity, thus far the patho-l physiologic mechanisms responsible for recurrent deep venous thrombosis, arteritis, and hemorrhage, usually 3 manifested as petechiae and purpura, are unclear. Patho-l logic examinations of patients with Behcet syndrome! generally reveal perivascular inflammatory changes (191) . Although oral and genital ulcers are the most common mucocutaneous manifestations, many develop skin ulcers as well (192) . The ocular manifestations are usually white patches of retinitis with hemorrhage, retinal vasculitis, optic neuritis, and cataract formation (193, 194) . Several reports have related Behcet syndrome to the development of myclodysplastic syndromes, but this requires confirmation ( 1~~,1~~~. Therapeutic agents suggested to be effective in Behcet syndrome include colchicine, prednisone, other immunosuppressives, dapsone, methotrexate, and thalidomide (197) (198) (199) .
Vascular defects associated with cardiopulmonary bypass
Poorly understood in the vasculature may happen during or after cardiopulmonary bypass (CPB) surgery. A syndrome of mild to moderate nonthrombocytopenic purpura accompanied by splenomegaly and atypical lymphocytosis following CPB has noted ~2~(~)~ , In this syndrome, purpura is usually benign, self limiting, and frequently manifests only after discharge from the hospital. One patient has been reported who developed post-CPB classical glomeruiar nephritis of the type seen with the allergic vasculitides. A:I~a, fats! purpura fulminans may also happen following CPB ~~~3 ~ ~: An inflam-~~ matory vasculitis may be associated with cardiopuimonnary bypass; however, the mechanisms are unclear. 1 I~rug·induce~d vasculitis Drug-induced vasculitis is common in clinical medi-; cin~, and very often neglected as a cause of petechiae and I purpura, skin necrosis, or frank gangrene. There are ' many mechanisms by which drugs may induce vasculitis and most do not significantly differ from the mechanisms i operative in circulating immune complex disorders. Fre-/ quently, however, the precise mechanisms by which j drugs induce vasculitis are poorly understood. There are ! several mechanisms by which drugs may induce vascular defects. These include the development of a specific antivessel antibody (202) , the development of circulating immune complexes, sometimes associated with cryoglobulinemia (203) , and more rarely, drug-induced indeppendent changes in vascular permeability. A characteristic, catastrophic, and cvell'-trhara~terized vasculitis asi sociated with warfarin anticoagulants should be familiar I to all (204) (205) (206) (207) (208) (209) . This and hemorrhagic skin vasculitis as I manifested by hemorrhagic skin infarction sometimes hats been associated with intravascular coagulatioñ~ i ~,~ i i ~ Most warfarin derivatives have been incrimi-, nnt~d: 90% of cases have been women and gangrene of ! the breast has happened in at least 25% of cases reported in the literature. The histologic features of this syndrome have been described quite well and show perivascular accumulations of inflammatory cells involving mainly the venules, with extensive thrombosis of the draining veins with little or no invasion of arterioles (212) . Typically, the clinical picture develops 3 to 10 days after starting therapy and bears little relationship to the prothrombin time. Many patients are protein C, protein S, or antithrombin-III deficient, and it is thought there is a sort period of hypercoagulability resulting from the initial of the procoagulant and anticoagulant systems of these patients when starting warfarin treatment y ; ~2i3,2I4.). However, some patients with this disorder have normal protein C, protein S, and antithrombin-III levels and in these instances the mechanism may be that 'of a direct toxic effect on the endothelium by warfarin.
Many patients ~ui~I respond to heparin/lo'w-moleculari weight heparin therapy (212) (213) (214) . However, unfraction-iit~d heparin has been associated with the above syndrome in ~.vit~ proteins ~ or S defects and in the presence or absence of heparin-induced thrombocytopenia with or without paradoxical thrombosis (215) . The most common drugs causing vascular problems are listed in Table 14 .
LABORATORY FINDINGS IN VASCULAR DEFECTS
The primary laboratory screening test for a vascular 'disorder or a platelet function defect is the standardized (4, 219) . The aspirin tolerance test consists of administering 600 mg of aspirin and repeating the TBT in the opposite antecubital fossa 2 hours postaspirin. Most individuals will prolong about 2 to 3 minutes ; however, the ingestion of 600 mg aspirin will unmask an underlying vascular or platelet function defect and render the repeat bleeding time about three times the baseline TBT, usually 20 to 30 minutes (4) . Once an abnormal TBT, petechiometer test, or aspirin tolerance test has been shown in the appropriate clinical setting, along with a normal platelet count, the differential diagnosis is then between a platelet function or a vascular defect. To make this differential diagnosis, platelet function testing must next be done. including an evaluation for autoimmune disease, paraprotein disorders, possibly a connective tissue or vascular biopsy, or other similar modalities will often be needed to make a definitive diagnosis (4) .
There are many tests now available to the hemostasis ' laboratory to assess vascular function; these consist of presence of a vascular disorder is usually documented in the hemostasis laboratory; however, once the presence of a vascular disorder has been established, the specific diagnosis usually falls outside the realm of the hemostasis laboratory and other types of laboratory procedures, including special biopsies and staining, are needed for a definitive diagnosis. Table 15 summarizes the laboratory assays for evaluation of vascular defects.
SUMMARY
This review has summarized the more important diseases that may be accompanied by or lead to a disorder of hemostasis or thrombosis via alterations of the vasculature. It is to be stressed that the vascular component of hemostasis is often overlooked by clinicians carping for patients with disorders of hemostasis and thrombosis. It should be appreciated that the vasculature is intricately related to the coagulation protein system and to platelets when involved in thrombohemorrhagic diatheses. Although many vascular disorders may lead to hemorrhage or thrombosis, it must be appreciated that often it is impossible to discern between a primary vascular defect/damage and a defect that has been induced by platelet activation/dysfunction or procoagulant abnormalities.
Ac~nu~led ' ~nts. In this and subsequent issues, members of the Editorial Board and Board of Directors of the International Academy of Clinical and Applied Thrombosi@/Hemostasis will author State-of-the-An Reviews. These are intended to bring readers and members of the Academy up to date on common as well as complex issues in thrombosis and hemostasis and will also help those individuals asking for reading and review material in preparation for taking the board certification or specialty recognition examinations in thrombosis, hemostasis, and vascular medicine. This series of special review articles is made possible by an 
